2022 July
-1
archive,date,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

July 2022

Home > 2022 > July

18 Jul

Posted at 11:30h in Blogs by

Brentuximab vedotin plus standard chemotherapy (B+AVD group) showed a 6-year OS of 93.9% compared to standard chemotherapy (ABVD group) 89.4% in patients with previously untreated, stage III/ IV HL. Fewer patients in the B+AVD group received subsequent therapy, including transplantation, and had fewer second cancers compared to the ABVD group. (Ref: Ansell SM et al. N Engl J Med. July 13, 2022)
#oncologyresearch #clinicaldevelopment
https://www.linkedin.com/feed/update/urn:li:activity:6954775520706191360